3%) had an ASA I-II (9 in each group), whereas 10 (35.7%) had an ASA III. The mean duration of anesthesia was 3.27 ± 0.48 h, with no differences FK228 price between the TIVA-TCI and BAL groups (p = 0.42). All patients showed a high grade urothelial carcinoma (G3). No significant differences between the two groups were observed regarding tumor size, invasiveness (pT), lymph node involvement (pN), body mass index, time of surgery and hospitalization. Table 1 Clinical characteristics VEGFR inhibitor of patients with bladder cancer who underwent radical

cystectomy with TIVA-TCI or BAL anesthesia   All cancer patients (n. 28) TIVA-TCI (n. 14) BAL (n. 14) P TIVA-TCI vs. BAL Age (yrs) 62.04 ± 8.63 63.2 ± 6.8 61.2 ± 10.8 0.57 Sex , n (%)          males 23 (82.1%) 12 (85.7%) 11 (78.6%) 0.62  females 5 (17.9%) 2 (14.3%) 3 (21.4%)   Histological type of cancer          High grade urothelial carcinoma 28 (100%) 14 (100%) 14 (100%) 1.00 pT, n (%)          1-2 11 (39.3%) 6 (42.9%) 5 (35.7%) 0.70  3 17 (60.7%) 8 (57.1%) 9 (64.3%)   pN, n (%)          0 22 (78.6%) 12 (85.7%) 10 (71.4%) 0.34  1 2 (7.1%) 0 2 (14.3%)    2

4 (14.3%) 2 (14.3%) 2 (14.3%)   ASA, n (%):          I-II 18 (64.3%) CP673451 molecular weight 9 (64.3%) 9 (64.3%) 1.00  III 10 (35.7%) 5 (35.7%) 5 (35.7%)   Weight (BMI ) 25.8 ± 4.2 27.1 ± 5.9 25.1 ± 3.0 0.55 Time of surgery (h) 3.12 ± 0.59 3.08 ± 0.58 3.17 ± 0.56 0.27 Time of anaesthesia (h) 3.27 ± 0.48 3.18 ± 0.45 3.35 ± 0.51 0.42 Time of hospitalization (days) 13.29 ± 1.00 13.58 ± 0.99 13.00 ± 0.95 0.16 Metastasis

after surgery, n (%) 4 (14.3%) 1 (7.1%) 3 (21.4%) 0.28 Death from cancer, n (%) 5 (17.9%) 1 (7.1%) 4 (28.6%) 0.14 Death from any cause, n (%) 7 (25.0%) 2 (14.3%) 5 (35.7%) 0.19 Values are expressed in absolute values or mean ± SD. During surgery, decreases in hematocrit and hemoglobin concentration were observed in both groups, but intra-operative blood loss was similar (Table 2). Transfusion of allogenic blood and Ketotifen autotransfusion were performed in 11 and 6 patients, respectively (5 and 3 in the TIVA-TCI group and 6 and 3 in the BAL group, respectively), with no significant differences in the number of transfusions between groups. Also, the volume of electrolyte solution administered during anesthesia was similar in the TIVA-TCI and BAL groups (Table 2). Similarly, no statistical differences were observed between groups regarding hemodynamic and respiratory parameters, tissue perfusion markers, temperature, or glucose levels (Table 2). Table 2 Perioperative clinical data of patients with bladder cancer who underwent radical cystectomy with TIVA-TCI or BAL anesthesia   TIVA ( n. 14) BAL (n. 14) P TIVA vs. BAL HB (g/dl)        Pre-anaesthesia 13.51 ±1.80 14.42 ± 1.33 0.14  Intraoperative 9.82 ±1.63 10.43 ± 1.82 0.47  5 days post-surgery 9.63 ±1.24 9.70 ± 1.35 0.86 HCT (%)        Pre-anaesthesia 39.53 ± 5.23 42.55 ± 4.47 0.14  Intraoperative 28.2 ±5.12 30.33 ± 5.41 0.52  5 days post-surgery 29.16 ±4.85 28.32 ± 3.80 0.65 Blood loss (ml) 1596 ± 365 1539 ± 418 0.